Investigating the Effect of Ocrelizumab in African Americans and Caucasians With Relapsing Multiple Sclerosis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-60
SponsorWayne State University
About this trial
The investigators intend to examine the effects of ocrelizumab use in African American multiple sclerosis disease course compared to Caucasian disease course utilizing imaging measures with magnetic resonance imaging (MRI) and optical coherence tomography angiography (OCT-A)..
Eligibility criteria
Qualifiers
Patients who have chosen to start ocrelizumab and for whom ocrelizumab is determined to be the most appropriate standard-of-care disease modifying therapy (DMT) by the treating neurologist.
May be treatment naive, or had suboptimal response to no more than one DMT after an adequate course of treatment (defined as treatment duration of 6+ months).
Age 18 to 60 years old.
Ethnicity: self-identified as African American or Caucasian.
Disqualifiers
Treatment with another monoclonal antibody, including but not limited to natalizumab, alemtuzumab, daclizumab.
Failed 2 or more DMTs.
Treatment with immunosuppressant agents, such as chemotherapeutic agents.
Claustrophobia.
Trial design
Treatments tested in this trial
- Observation of Ocrelizumab as Treatment in RRMS Patients
Treatment groups
80 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov